Global Lomitapide Pregnancy Exposure Registry

Global Lomitapide Pregnancy Exposure Registry

To evaluate the outcomes of pregnancy in women treated with lomitapide.

To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30 days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of primary interest are major congenital anomalies.

Inclusion Criteria:

• Pregnant females exposed to lomitapide at any time within 30 days prior to first day of the LMP or during pregnancy.

Exclusion Criteria:

• Patients who are unable or unwilling to provide written informed consent or assent are not eligible to participate in the PER.